Determining mild, moderate, and severe pain equivalency across pain-intensity tools in nursing home residents

Jones, Katherine R.; Vojir, Carol P.; Hutt, Evelyn; Fink, Regina

doi:10.1682/jrrd.2006.05.0051

Cited by 156 publications

(124 citation statements)

References 29 publications

Supporting

Mentioning

115

Contrasting

Unclassified

Order By: Relevance

“…It is a self-report measuring the outcome expectancy (OE) and selfefficacy expectancy (EE) for labour and birth. This questionnaire was composed of 62 items and divided into four subscales categorized in two parts: [23,24]. It was offered to women during pain to rate their pain score.…”

Section: Data Collectionmentioning

confidence: 99%

Antenatal Education on Childbirth Self-Efficacy for Egyptian Primiparous Women: A Randomized Control Trial

El-Kurdy¹,

Hassan²,

Hassan³

et al. 2017

IOSR JNHS

View full text Add to dashboard Cite

Section: Data Collectionmentioning

confidence: 99%

Antenatal Education on Childbirth Self-Efficacy for Egyptian Primiparous Women: A Randomized Control Trial

El-Kurdy¹,

Hassan²,

Hassan³

et al. 2017

IOSR JNHS

View full text Add to dashboard Cite

“…Previous studies have attempted to identify pain intensity cutoff points using diverse measuring scales (16)(17)(18). However, it has been determined that cutoff points vary, depending on pain type, chronicity, diagnosis, age, co-morbid conditions, cultures and the interference of pain with various activities (including enjoyment of life, daily activity, walking, mood, sleep and work) (19). Thus, VAS scores for pain for classifying patients with severe or very severe pain have varied in different studies (19).…”

Section: Methodsmentioning

confidence: 99%

Smoking and female sex as key risk factors associated with severe arthralgia in acute and chronic phases of Chikungunya virus infection

Delgado‐Enciso

Paz‐Michel²,

Melnikov

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

Abstract. Arthralgia is a potentially incapacitating condition and a persistent symptom in chronic or acute episodes of Chikungunya fever caused by infection with the Chikungunya virus (CHIKV). To the best of our knowledge, there are no reports on risk factors associated with the intensity of arthralgias in typical acute episodes of the disease. Although a number of studies have reported on risk factors associated with the development of the chronic stage of the disease, smoking habits have not been analyzed. Smoking is an interesting factor to consider since it is the main environmental risk factor for the development of rheumatoid arthritis (RA), a similar disease to CHIKV in many aspects. In the present study, 140 patients infected with CHIKV were assessed for risk factors associated with severe arthralgia intensity in the acute phase (pain of 9/10 on the visual analog scale of 0-10) and moderate to severe intensity (according to the Routine Assessment of Patient Index Data 3) 3.5 months after infection in patients that experienced the chronic phase of the disease. Women and smokers were 2-to 3-times more likely to experience severe pain in the acute and chronic stages. Likewise, the presence of severe arthralgia during the acute disease phase resulted in a 4-fold increased risk for entering the chronic phase. Smoking was a more important risk factor in males compared with females. Smoking resulted in a 20-fold increased risk for severe arthralgia during the acute phase in men, as well as a 10-fold increased risk for developing chronic disease with moderate-to-severe pain 3.5 months after the acute stage. The presence of rash, headache, muscular weakness or conjunctivitis in the acute phase, the presence of diabetes and age >40 years were considered significant risk factors due to their influence on illness progression. In conclusion, smoking and female sex were the main risk factors associated with development of severe joint pain in the acute and chronic phases of Chikungunya fever. These risk factors are similar to those associated with the development and severity of RA, possibly because the two diseases share pathophysiological mechanisms, including elevated interleukin-6 levels.

show abstract

“…The average baseline VAS of pain (mean±SD) in all included studies varied from 4.90±1.72 (Maneenual, 2010) to 6.56±0.91 (Srimongkol, 2007). These scores were categorized as moderate pain (Jones, 2007).…”

Section: Study Characteristicsmentioning

confidence: 99%

Efficacy and safety of Derris scandens (Roxb.) Benth. for musculoskeletal pain treatment: A systematic review and meta-analysis of randomized controlled trials

Puttarak

Sawangjit

Chaiyakunapruk

2016

Journal of Ethnopharmacology

View full text Add to dashboard Cite

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. scandens showed no different relative risk with NSAIDs. The major adverse events were gastrointestinal symptoms. ConclusionD. scandens may be considered as an alternative for musculoskeletal pain reduction. 3 Graphical abstractAbbreviations

show abstract

Determining mild, moderate, and severe pain equivalency across pain-intensity tools in nursing home residents

Cited by 156 publications

References 29 publications

Antenatal Education on Childbirth Self-Efficacy for Egyptian Primiparous Women: A Randomized Control Trial

Antenatal Education on Childbirth Self-Efficacy for Egyptian Primiparous Women: A Randomized Control Trial

Smoking and female sex as key risk factors associated with severe arthralgia in acute and chronic phases of Chikungunya virus infection

Efficacy and safety of Derris scandens (Roxb.) Benth. for musculoskeletal pain treatment: A systematic review and meta-analysis of randomized controlled trials

Contact Info

Product

Resources

About